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Abstract
Background: Rhabdoid Tumors (RTs) are highly aggressive pediatric malignancies with poor prognosis. There are
currently no standard or effective treatments for RTs in part because treatments are not designed to specifically
target these tumors. Our previous studies indicated that targeting the cyclin/cdk pathway is a novel therapeutic
strategy for RTs and that a pan-cdk inhibitor, flavopiridol, inhibits RT growth. Since the toxicities and narrow
window of activity associated with flavopiridol may limit its clinical use, we tested the effect of combining
flavopiridol with 4-hydroxy-Tamoxifen (4OH-Tam) in order to reduce the concentration of flavopiridol needed for
inhibition of RTs.
Methods: The effects of flavopiridol, 4OH-Tam, and their combination on RT cell cycle regulation and apoptosis
were assessed by: i) cell survival assays, ii) FACS analysis, iii) caspase activity assays, and iv) immunoblot analysis.
Furthermore, the role of p53 in flavopiridol- and 4OH-Tam-mediated induction of cell cycle arrest and apoptosis
was characterized using RNA interference (siRNA) analysis. The effect of p53 on flavopiridol-mediated induction of
caspases 2, 3, 8 and 9 was also determined.
Results: We found that the combination of flavopiridol and 4OH-Tam potently inhibited the growth of RT cells.
Low nanomolar concentrations of flavopiridol induced G2 arrest, which was correlated to down-modulation of
cyclin B1 and up-regulation of p53. Addition of 4OH-Tam did not affect flavopiridol-mediated G2 arrest, but
enhanced caspase 3,7-mediated apoptosis induced by the drug. Abrogation of p53 by siRNA abolished flavopiridol-
induced G2 arrest, but enhanced flavopiridol- (but not 4OH-Tam-) mediated apoptosis, by enhancing caspase 2 and
3 activities.
Conclusions: Combining flavopiridol with 4OH-Tam potently inhibited the growth of RT cells by increasing the
ability of either drug alone to induce caspases 2 and 3 thereby causing apoptosis. The potency of flavopiridol was
enhanced by abrogation of p53. Our results warrant further studies investigating the combinatorial effects of
flavopiridol and 4OH-Tam as a novel therapeutic strategy for RTs and other tumors that have been shown to
respond to flavopiridol.
Background
RTs, including Malignant Rhabdoid Tumors (MRT),
Atypical Teratoid and Rhabdoid Tumors (AT/RT), and
extra renal rhabdoid tumors (ERRT) are rare, but highly
aggressive pediatric solid tumors with poor prognosis
[1]. Current therapy for RTs includes surgical resection,
radiation therapy, and/or chemotherapy with empirically
selected and highly toxic chemotherapeutics, which are
largely ineffective [2,3]. Despite aggressive treatment,
mean survival with surgical intervention alone is only
3 months and with adjuvant chemotherapy and radio-
therapy is only 8 months [4]. Therefore, strategies based
on understanding the genesis of RTs will aid in the
development of novel therapies. RTs are characterized
by biallelic deletions and/or mutations in INI1/hSNF5,a
tumor suppressor and component of the chromatin
remodeling SWI/SNF complex [5,6]. Reintroduction of
INI1/hSNF5 into RT cells induces G1 cell cycle arrest
and senescence. INI1/hSNF5 mediates these effects by
directly activating p16
Ink4a by recruiting the SWI/SNF
complex and by directly repressing cyclin D1 by
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that cyclin D1 is de-repressed in human and mouse RTs
and is required for rhabdoid tumorigenesis in mouse
models [9,11,12]. Such studies indicated that therapeutic
targeting of cyclin D1 and its pathway could be an effec-
tive and novel therapeutic strategy for RTs.
We previously reported that down-modulating cyclin
D1 and inhibiting cyclin dependent kinases (cdks) using
either flavopiridol or a combination of N-(4-hydroxy-
phenyl)retinamide (4-HPR) with 4OH-Tam is effective
in inhibiting RTs in vitro and in xenograft tumor mod-
els in vivo [11,13]. The effectiveness of 4-HPR and flavo-
piridol was correlated with down-modulation of cyclin
D1 in xenograft tumors [13].
Flavopiridol is one of the first cdk inhibitors to enter
clinical trials. Although early clinical trials were unsuc-
cessful, design of a novel schedule of administration
based on the in vitro and in vivo pharmacokinetic mod-
eling of flavopiridol’se f f e c th a ss h o w np r o m i s i n ge f f i -
cacy in refractory chronic lymphocytic leukemia [14].
Phase I trials of flavopiridol in children have revealed
that its toxicity profile, pharmacokinetics, and maximum
tolerable dose were similar to that in adults, indicating
that using flavopiridol in RT patients, a largely pediatric
population, is feasible [15].
The effects of flavopiridol on cancer cells are varied
and cell type dependent. In many cell lines flavopiridol
leads to G1 arrest due to down-modulation of cyclin D1
and inhibition of its pathway by various mechanisms
[16-24]. In other cells, flavopiridol induces G2 arrest, in
part due to its potent ability to inhibit cdk 7, 8 and 9
activities [25]. Flavopiridol also inhibits transcription of
Mdm-2 resulting in the accumulation of its proteolytic
target, p53, which triggers p21
Waf1 up-regulation, cyclin
B1 down-regulation, and ultimately G2 arrest [26]. Fla-
vopiridol can induce apoptosis at nanomolar concentra-
tions and its pro-apoptotic action is either caspase-
dependent or -independent [25]. Flavopiridol can trigger
apoptosis by activation of caspases 2, 3 and 8 [27] or by
activation of apoptosis inducing factor (AIF) via its
release from the mitochondria [28]. At this point, the
mechanism of action of flavopiridol in RT cells is not
completely understood.
Since flavopiridol can be toxic at high doses, recent
studies have focused on combining low concentrations
of flavopiridol with other anti-neoplastic agents [29,30].
In this report, we tested the combination of flavopiridol
with 4OH-Tam to determine its ability to increase ther-
apeutic efficacy against RT cells. 4OH-Tam inhibits
tumor cell growth in part by deregulating cyclins and
cdks. Breast cancer cells over-expressing cyclin D1 are
resistant to 4OH-Tam and the level of cyclin D1 is
negatively correlated to responsiveness to 4OH-Tam
[31-34]. 4OH-Tam suppresses the growth of estrogen-
receptor positive tumors by down-modulating cyclin D1
[35]. Furthermore, treatment of tumor cell lines with
10μM 4OH-Tam induces the expression of p21
Waf1 and
p27
Kip1, which are known to block the effects of cyclin
D1 [36]. Previous studies have demonstrated that 4OH-
Tam is effective in inducing cytotoxic effects in RT cells
[37]. In this study it was demonstrated that the expres-
sion of ERa receptor in RT cells is variable and that the
cytotoxic effects of 4OH-Tam are independent of ERa
expression [37]. Since the efficacy of flavopiridol in
xenograft RTs was correlated with down-modulation of
cyclin D1 and up-regulation of p21
Waf1[13], we consid-
ered combining 4OH-Tam with flavopiridol to enhance
its therapeutic efficacy in RT cells.
We report here that the combination of flavopiridol
with 4OH-Tam potently inhibited the survival of RT
cells. A low concentration of flavopiridol (100 nM)
induced G2 arrest in RT cells in a p53-dependent man-
ner and resulted in a moderate amount of apoptosis.
Addition of 4OH-Tam significantly increased flavopiri-
dol-mediated apoptosis. Down-modulation of p53 did
not affect 4OH-Tam-induced cytotoxicity, but signifi-
cantly enhanced flavopiridol-mediated apoptosis.
Furthermore, we found that the increased cytotoxic
effects of flavopiridol and 4OH-Tam correlated with
augmentation of caspase 2 and 3 activities and that
these effects were independent of p53. These studies
indicate that the combination of flavopiridol and 4OH-
Tam can be effective in potently inhibiting RT cell
growth and is potentially a novel therapeutic strategy
against RTs.
Methods
Cell culture and drug treatment
MON [6], G401 (American Type Culture Collection),
and A204 cells (American Type Culture Collection)
were maintained in RPMI supplemented with 10% fetal
bovine serum, 50 U/ml penicillin, 50 μg/ml streptomy-
cin, and 2 mM L-glutamine. For drug studies, the cells
were transferred one day before drug treatment to
RPMI containing 10% charcoal and dextran treated fetal
bovine serum (HyClone, Cat. SH30068.03). Flavopiridol
was obtained from the CTEP program at NCI (courtesy
of Dr. Colevas). 4OH-Tam and pan-caspase inhibitor
z-VAD-FMK were purchased from SIGMA (Catalogue
#H7904) and Promega (Catalogue #G7232) respectively.
Cell Survival analysis
8,000 cells/well (MON and A204) or 6,500 cells/well
(G401) were plated in 96-well plates and treated with
different concentrations/combinations of drugs, using
the epMotion 5070 automated liquid handler system
(Eppendorf). The CellTiter 96 AQueous One Solution
Cell Proliferation Assay was used to determine cell
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of cell survival, IC50, and drug combination effects were
performed according to previously described methods
[11].
FACS Analysis
Propidium iodide staining and FACS analysis were
performed as described previously [9]. Annexin stain-
ing was performed using Annexin V-FITCH Apoptosis
Detection Kit I (BD Pharmingen Catalogue #556547)
according to the manufacturer’s instructions. Data
was elaborated using CellQuest Pro program (BD
Pharmingen).
Statistical analysis
Data was analyzed using GraphPad Prism by applying
the ANOVA test or t-test.
Immunoblot analysis
Immunoblot analysis was carried out as described pre-
viously with minor modifications [9]. Dry milk was used
as a blocking agent for the following antibodies: p53
(Santa Cruz Catalogue #sc-126), cyclin A (Santa Cruz
Catalogue #sc-239), cyclin B1 (Santa Cruz Catalogue
#sc-752), cyclin E (LabVision Catalogue #MS-870-P),
cyclin D1 (Lab Vision Catalogue #RB-010-P), E2F-1
(Santa Cruz Catalogue #sc-251), GAPDH (Chemicon
Catalogue #MAB374) and Rb (Santa Cruz Catalogue
#sc-102); and bovine serum albumin for the following
antibodies: cdk 2 (Santa Cruz Catalogue #sc-163), cdk 4
(Santa Cruz Catalogue #sc-260), cdk 6 (Santa Cruz Cat-
alogue #sc-7961) and p21 (Calbiochem Catalogue
#OP64). Chemiluminescence detection was achieved
using SuperSignal West Pico Chemiluminescence Sub-
strate (Pierce Catalogue #34080).
RNA interference
MON cells were plated at 300,000 cells/well in 6-well
plates one day before transfection. Cells were transfected
using DharmaFECT siRNA transfection reagent (Dhar-
macon Catalogue #T-200(01-07)-01) according to the
manufacturer’s instruction and using previously pub-
lished p53 siRNA (Qiagen Catalogue #024849) and con-
trol (Cy3-Luciferase GL2 Duplex, Dharmacon Catalogue
#D-001110-01-05). One day post-transfection, cells were
split into 50,000 cells/well using medium containing
10% charcoal and dextran treated fetal bovine serum,
for drug treatment the following day.
Immunocytochemistry
MON cells were grown on glass coverslips and treated
with drugs. Cells were fixed with 4% paraformaldehyde-
PBS solution for 10 minutes, and permeabilized with
0.1% triton-PBS solution for 10 minutes. Cover-slips
were treated for 1 hour at room temperature with 1:250
diluted ap21 antibody (Calbiochem Catalogue #OP64).
Staining was detected using the Vectastain ABC kit
(Vector Laboratories Catalogue #PK-6102) according to
manufacturer’s instruction. Peroxidase staining was
developed using the DAB enhanced liquid substrate sys-
tem (SIGMA Catalogue #D3939-1SET). The percentage
of cells with nuclear expression of p21 was quantified by
counting 250 to 300 individual cells, noting whether or
not their nuclei showed positive staining above the
background. The background staining was defined as an
intensity of staining at or below the intensity of the
negative control (i.e. any background staining that
occurred in the absence of a p21-specific antibody).
Caspase-profiling assays
Caspase 3/7 Assay was performed using the Caspase-Glo
3/7 Assay kit (Promega Catalogue #G8093). Caspase
activity profiling assays were performed using ApoAlert
Caspase Profiling Plate (Clontech Catalogue #630225),
according to the manufactures’ instruction with minor
modification, using 50 μg of protein for each well of the
assay.
Results and Discussion
Combination treatment with flavopiridol and 4OH-Tam
inhibits the growth of RT cells
To determine the effect of combining flavopiridol with
4OH-Tam, we treated MON, G401, and A204 RT cells
with increasing concentrations of flavopiridol (0 to 200
nM) in combination with 2.5, 5.0, or 10.0 μM4 O H -
Tam for two days. Flavopiridol inhibited RT cell growth
with IC50 values of ~50-100 nM, with MON cells show-
ing an intermediate level of sensitivity compared to
G401 and A204 cells (Figure 1A-D). Exposure of all
cells to flavopiridol and 4OH-Tam in combination
resulted in a dramatic reduction in IC50 values, with 10
μM 4OH-Tam reducing the IC50s to ~0.12-0.2 nM (Fig-
ure 1A-D). Furthermore, increasing the time of exposure
to the combination of drugs enhanced the inhibitory
effects in both MON and G401 cells (compare Figures
1A and 1B with Figure 2A, B, E, and 2F). Bar graphs
derived from the data in Figure 2A and 2E are given to
show the decreases in cell survival induced by the speci-
fic concentrations of the drugs after three days of expo-
sure (Figure 2D and 2H). We also tested the effect of
4OH-Tam alone and found that 4OH-Tam decreased
cell survival significantly (Figure 2C and 2G). However,
increasing time of exposure to 4OH-Tam alone from
one to three or five days, did not result in further
decreases of cell survival (Figure 2C and 2G). Thus,
while the flavopiridol and 4OH-Tam combination
resulted in a time dependent decrease of survival, the
effect of 4OH-Tam alone was independent of time of
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tions of very low concentrations of flavopiridol (~ 0.2
nM) and 10 μM 4OH-Tam decreased cell survival by
80% in MON and 99% in G401 cells (Figure 2B and 2F).
These results indicated that treatment with low concen-
trations of flavopiridol in combination with 4OH-Tam
for prolonged periods potently inhibits RT cell growth.
Induction of apoptosis by flavopiridol and 4OH-Tam
To determine the mechanism of growth inhibition by
these drugs, we studied MON cells which showed inter-
mediate responses to the combination of drugs with an
intermediate level of 4OH-Tam (5 μM) and duration of
treatment. MON cells were exposed to combinations of
flavopiridol and 5 μM 4OH-Tam for two days and sub-
jected to cell cycle analysis. Treatment of cells with
5 μM 4OH-Tam alone resulted in G1 arrest (p = 0.0117,
Figure 3A). Our previous results indicated that flavopiri-
dol at 200-400 nM induces G1 arrest [13]. However,
treatment with 100 nM flavopiridol induced G2 arrest in
t h ep r e s e n c eo ra b s e n c eo f4 O H - T a m( p =0 . 0 0 3 9a n d
p = 0.0003, respectively, Figure 3A) indicating that the
stage of cell cycle arrest induced is dose-dependent.
These results also indicate that G2 arrest induced by fla-
vopiridol is dominant over 4OH-Tam-induced G1 arrest.
Analysis of the sub-G1 fraction of cells after single or
combination treatment indicated that the percentage of
sub-G1 cells increased in a dose-dependent manner
upon treatment with flavopiridol, which was further
enhanced by combination with 4OH-Tam (Figure 3B).
Very high levels of cell death are induced by these treat-
ments and this likely plays the major role, compared to
induction of cell cycle arrest, in inducing cytotoxicity in
response to treatment with these drugs. To determine if
cell death was due to apoptosis, the cells were stained
for annexin (indicative of apoptosis) and propidium
iodide (indicative of necrosis) and the percentage of
cells positive for either or both stains was determined
b yF A C S( F i g u r e3 C ) .W h i l et h ep e r c e n t a g eo fn e c r o t i c
or dead cells remained largely unchanged, there was a
dose-dependent increase in annexin-positive cells
demonstrating that combination treatment with flavopir-
idol and 4OH-Tam induces significant levels of
apoptosis.
Induction of apoptosis by flavopiridol and 4OH-Tam is
caspase-dependent
Since it is known that flavopiridol can induce apoptosis
by caspase-dependent or caspase-independent mechan-
isms, we investigated the effect of a caspase inhibitor on
drug-induced cytotoxicity. MON cells were exposed for
two days to flavopiridol and 4OH-Tam in the presence
or absence of the pan-caspase inhibitor, Z-VAD-FMK,
and FACS analysis was carried out to assess the effects
on cell cycle and apoptosis. The results indicated that
drug-induced cell cycle arrest was unaffected (p =
0.0458 and p = 0.0025 for G1-arrest induced by 100 nM
flavopiridol with and without 4OH-Tam respectively)
Figure 1 Inhibition of rhabdoid tumor growth by flavopiridol and 4OH-Tam. A-C. Survival curves of MON (A), G401 (B), and A204 (C) cells
treated with flavopiridol in the presence and absence of 4OH-Tam for two days. D. Table of IC50 values as approximated from A-C. Flavo =
flavopiridol; 4OHT = 4OH-Tam.
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Page 4 of 13Figure 2 Inhibition of rhabdoid tumor growth by flavopiridol and 4OH-Tam after prolonged treatment. A, B, E, and F. Survival curves of
MON (A-B)) or G401 (E-F) cells treated with flavopiridol in the presence and absence of 4OH-Tam for three (A and E) and five (B and F) days.
C and G. Survival curves of MON (C) or G401 (G) cells treated with 4OH-Tam for one, three, and five days. D and H. Bar graph representing the
decreases in survival of MON (D) or G401 (H) cells after treatment with specific concentrations of drugs for three days. (Flavo = flavopiridol;
4OHT = 4OH-Tam).
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with or without 4OH-Tam was significantly inhibited by
Z-VAD-FMK (p < 0.0001, Figure 4B). This established
that cell death induced by flavopiridol, 4OH-Tam, or
their combination is mediated by caspase-dependent
apoptosis in RT cells. We further investigated the
kinetics of induction of caspase 3 and 7 activities upon
drug treatment. The results indicated that, while
flavopiridol induced peak caspase 3 and 7 activities at
six hours, 4OH-Tam exhibited delayed kinetics with
peak induction at 12 hours. Interestingly, combination
of 4OH-Tam and flavopiridol elevated caspase 3 and 7
Figure 3 Induction of cell cycle arrest and apoptosis by
flavopiridol and 4OH-Tam: A. Diploid cell cycle profile determined
by FACS analysis of MON cells treated with flavopiridol and 4OH-
Tam for two days; B. Percentage of MON cells at sub-G1 when
exposed for two days to flavopiridol and 4OH-Tam C. Percentage of
apoptotic (annexin positive), necrotic (PI positive) and dead (both
annexin and PI positive) MON cells when exposed for two days to
flavopiridol and 4OH-Tam.
Figure 4 Effect of caspases on flavopiridol- and 4OH-Tam-
induced cell cycle arrest and apoptosis: A. Diploid cell cycle
profile determined by FACS analysis of MON cells treated with
Flavopiridol and 4OH-Tam for two days in the presence of pan-
caspase inhibitor Z-VAD-FMC (Compare to Figure 2A); B. Percentage
of MON cells at sub-G1 when exposed for two days to flavopiridol
and 4OH-Tam, in the absence and presence of pan-caspase
inhibitor Z-VAD-FMC (CI). C. Kinetics of induction of caspase 3/7
activity in MON cells by flavopiridol and 4OH-Tam. The diagram
illustrates the fold increase in caspase 3/7 activity at various time
points after treatment. F100 = 100 nM flavopiridol; T5 = 5 μM
4OH-Tam.
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Page 6 of 13activities at both 6 and 12 hours (Figure 4C). These
results suggest that combination of flavopiridol and
4OH-Tam could increase apoptosis by inducing and
prolonging caspase 3/7 activities.
Mechanism of G2 arrest mediated by flavopiridol and
4OH-Tam
To determine the mechanism of cell cycle arrest
induced by flavopiridol and 4OH-Tam, we examined the
expression levels of several cell cycle regulatory and
tumor suppressor proteins in the presence and absence
of drugs. 100 nM flavopiridol induced p53 and p21
Waf-1
and repressed cyclin B1, consistent with the observed
G2 arrest (Figure 5A). We found that the majority of
cyclins and cdks, including cyclins D1, A and E, and
cdks 2, 4 and 6 were unaffected by concentrations of fla-
vopiridol ≤ 100 nM (Figure 5A). Interestingly, the pre-
sence of 4OH-Tam did not significantly alter the effects
of flavopiridol on cyclin and cdk expression, but further
decreased the level of pRb protein and phosphorylation
(Figure 5A compare lanes 4 and 8). We also observed
differential effects on pRb phosphorylation. Concentra-
tions of flavopiridol ≤ 25 nM increased the level of
phosphorylated pRb (Figure 5A lanes 2 and 3), but 100
nM dramatically decreased the phosphorylated form of
pRb (Figure 5A lane 4). Addition of 4OH-Tam
Figure 5 Effect of flavopiridol and 4OH-Tam on expression of cell cycle regulatory proteins: A. Immunoblots of various cell cycle proteins
in the presence and absence of flavopiridol and 4OH-Tam, after two days of treatment. B. ap21 immunocytochemistry of MON cells treated
with: no drug (panel 1), 100 nM flavopiridol (panel 2), 5 μM 4OH-Tam (panel 3), or both 100 nM flavopiridol and 5 μM 4OH-Tam (panel 4). Note
the strong nuclear staining in the drug treated cells (panels 2-4). C. Quantitation of MON cells with nuclear p21 using a-p21
immunocytochemistry after treatment with no drug, 100 nM flavopiridol, 5μM 4OH-Tam, or 100 nM flavopiridol and 5μM 4OH-Tam. Average
values represent counting of more than 200 cells in four random fields for each treatment group.
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pRb at the 25 nM concentration (Figure 5A lane 7).
However, 4OH-Tam had no effect on 100 nM flavopiri-
dol-induced inhibition of pRB phosphorylation, consis-
tent with the observed dominant effect of 100 nM
flavopiridol in inducing G2 arrest.
Flavopiridol induced p21
Waf-1 expression in RT cells
Our previous analysis indicated that flavopiridol efficacy
in mouse xenografts correlated to both down-modula-
tion of cyclin D1 and up-regulation of p21
Waf-1 [13].
Therefore, we examined p21
Waf-1 levels upon flavopiri-
dol treatment with and without 4OH-Tam. We found
that p21
Waf-1 was up-regulated in a dose-dependent
manner upon treatment with flavopiridol (Figure 5A,
lanes 1-4), but 4OH-Tam alone only modestly up-regu-
lated p21
Waf-1(Figure 5A, compare lanes 1 and 5). We
also investigated the accumulation of nuclear p21
Waf-1
upon drug treatment by immunocytochemical analysis.
The results indicated that flavopiridol treatment led to
increased nuclear p21
Waf-1, which was further increased
upon addition of 4OH-Tam (Figure 5B and 5C). These
results were confirmed by quantifying the percentage of
cells with nuclear p21
Waf-1 (Figure 5C) and, taken
together, indicate that combination treatment results in
both increased protein levels and increased nuclear loca-
lization of p21
Waf-1.
Abrogation of p53 inhibited cell cycle arrest but
enhanced apoptosis induced by flavopiridol
The above studies pointed to the involvement of p21
Waf-1
in flavopiridol or flavopiridol plus 4OH-Tam-mediated
cytotoxicity. It has been established that p21
Waf-1 is a
downstream effector of p53 [38]. Furthermore, tumori-
genesis in Ini1 heterozygous mice is enhanced upon
abrogation of p53 [39]. Since p53 is up regulated upon
flavopiridol treatment, we further investigated its role. To
determine whether p53 is necessary for flavopiridol-
induced cell cycle arrest and/or apoptosis, RNA interfer-
ence was used to down-modulate p53 expression. Trans-
fection of RT cells with p53 siRNA slightly enhanced cell
proliferation (data not shown). As expected, flavopiridol
markedly increased p53 expression in cells transfected
with control siRNA (Cy3), but not in cells transfected
with p53 siRNA (Figure 6A, compare lanes 2 and 6).
FACS analysis of cells transfected with control or p53
siRNA and treated with single or combination drugs for
two days indicated that, while control siRNA did not
affect drug-induced cell cycle arrest (p = 0.0221 and p =
0.0035 for G1-arrest induced by 100 nM flavopiridol with
and without 4-OH-Tam respectively, Figure 6B), knock-
down of p53 resulted in abrogation of flavopiridol-
mediated G2 arrest both in the presence and absence of
4OH-Tam (p = 1.000 (not significant), Figure 6C). These
results indicated that p53 is necessary for flavopiridol-
mediated G2 arrest in RT cells.
Interestingly, knock-down of p53 demonstrated differ-
ential effects on flavopiridol and 4OH-Tam-mediated
apoptosis in RT cells. Knock-down of p53 had no effect
on 4OH-Tam-induced apoptosis indicating that 4OH-
Tam-induced apoptosis is independent of p53 (Figure
6D). However, p53-knockdown enhanced flavopiridol-
mediated apoptosis in the presence or absence of 4OH-
Tam (Figure 6D). These results indicated that p53 is
detrimental to flavopiridol-induced apoptosis in MON
cells. Additionally, these results indicated that flavopiri-
dol and 4OH-Tam induce apoptosis in RT cells by two
different mechanisms; flavopiridol-mediated apoptosis
being inhibited by p53 and 4OH-Tam-induced apoptosis
being independent of p53.
Role of caspases in flavopiridol and 4OH-Tam induced
apoptosis
Expression of p53 has been associated with resistance to
radiation-induced apoptosis in some cancers including
gliomas and keratinomas [40,41]. Many RTs are resis-
tant to chemotherapy and radiotherapy; however the
mechanistic basis for this resistance is not clearly under-
stood [42,43]. Based on our results we surmised that
induction of p53 by flavopiridol is counter-productive to
induction of apoptosis in RT cells. It has been reported
that p53 is expressed in a majority of RTs and sequence
analysis of mRNA does not show any abnormality in the
p53 coding region [44,45]. Therefore, understanding the
role of p53 in inhibiting drug-induced apoptosis might
shed light on the mechanism of drug resistance exhib-
ited by these tumors. Since flavopiridol increased p53
levels in RT cells, which was inversely correlated to
induction of apoptosis, we explored the possibility that
flavopiridol induced apoptosis through specific caspases.
We profiled the kinetics of induction of caspase 2, 3, 8
and 9 activities in RT cells in the presence or absence of
p53 and upon treatment with flavopiridol, 4OH-Tam, or
their combination.
Analysis of the activation kinetics of caspases 2, 3, 8
and 9 indicated that neither flavopiridol nor 4OH-Tam
induced caspase 8 and 9 activities in RT cells (Figure 7A
and 7B and Additional File 1A-C). Induction of caspases
2 and 3 was affected by treatment with flavopiridol and
flavopiridol with 4OH-Tam (p = 0.0022 for caspase 2
and p.0001 for caspase 3) and was correlated to p53
levels (p = 0.0074 for caspse 2 and p < 0.0001 for cas-
pase 3) (Figure 7C and 7D). Flavopiridol increased cas-
pase 2 and 3 activity two-fold within 6 hours and
abrogation of p53 allowed flavopiridol to increase cas-
pase 2 and 3 activity four-fold in the same time (Addi-
tional File 1D and 1G). Exposure of cells to flavopiridol
with 4OH-Tam caused an overall increase in caspase 2
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Page 8 of 13Figure 6 Effect of p53 knock-down on flavopiridol- and 4OH-Tam-induced cell cycle arrest and apoptosis: A. Immunoblot analysis to
indicate siRNA mediated knock-down of p53 in MON cells treated with flavopiridol and 4OH-Tam for two days B. Percentage of diploid MON
cells at various stages of cell cycle after treatment with control (Cy3) siRNA followed by treatment with flavopiridol and 4OH-Tam for two days.
Note the lack of G2 arrest upon drug treatment of p53-knock-down cells. C. Percentage of diploid MON cells at various stages of cell cycle after
p53 knockdown (using siRNA to p53) and treatment with flavopiridol and 4OH-Tam for two days. D. Percentage of MON cells in sub-G1 after
transfection with control (Cy3) or p53 siRNAs and exposed to flavopiridol and 4OH-Tam for two days.
Figure 7 Flavopiridol- and 4OH-Tam-induced caspase profiles in MON cells. A-D. Induction of caspase 8 (A), 9 (B), 2 (C), and 3 (D) activities
after 24 hrs of treatment with flavopiridol, 4OH-Tam, or the combination and treated with either control (Cy3) or p53 siRNA.
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Page 9 of 13and 3 activity, with maximum induction observed at 12
hours (Figure 7C and Additional File 1F and 1I). Abro-
gation of p53 led to a further increase in caspase 2 and
3 activity after combination treatment, similar to that
caused by flavopiridol alone (Figure 7C and Additional
File 1F and 1I). 4OH-Tam alone caused only slight
increases in caspase 2 and 3 activities in the presence or
absence of p53 (Figure 7C and Additional File 1E and
1H).
To demonstrate that induction of caspase 2 and 3
activities were specific, we treated MON cells in the
presence and absence of p53 and also in the presence
and absence of specific caspase 2 or 3 inhibitors. Cas-
pase 2 and 3 activities were determined at the 24 hr.
time point in all of the treatment conditions. We
found that treatment of cells with caspase 2 or cas-
pase 3 inhibitors significantly reduced the induction
of caspase 2 or 3 activities upon drug treatment
respectively. These results indicated that flavopiridol
and 4OH-Tam drug treatment selectively induces cas-
pases 2 and 3 in MON cells, as inhibitors to these
caspases eliminated these increases (Additional File 1J
and 1K).
Conclusions
Our report demonstrates, for the first time, that RT
cell growth and survival is potently inhibited by combi-
nation treatment with clinically achievable concentra-
tions of 4OH-Tam (2.5 or 5 μM) and flavopiridol
(< 200 nM). Since high concentrations of flavopiridol
may cause significant toxicities, and since only low
concentrations may be achievable in areas such as the
brain due to the blood brain barrier, our results pro-
vide a method to increase the efficacy of low concen-
trations of flavopiridol.
Flavopiridol and 4OH-Tam together induce a signifi-
cant increase in RT cell death. Induction of cell death
by flavopiridol and the combination of flavopiridol with
4OH-Tam is due to caspase-dependent apoptosis and
caspase-profiling assays indicate that these treatments
can potently induce caspases 2 and 3. In addition to
inducing cell death, these treatments also induce cell
cycle arrest. While our previous report indicated that
400 nM flavopiridol induces G1 arrest [13], this current
report indicates that 100 nM flavopiridol is sufficient to
cause G2 arrest indicating that flavopiridol potently
induces cell cycle arrest in a dose-dependent manner.
Flavopiridol-induced G2 arrest was correlated to down-
regulation of cyclin B1 and up-regulation of p53 and
p21
Waf-1. On the contrary, 4OH-Tam inhibited p53
expression; however, this effect was nullified by addition
of 100 nM flavopiridol, explaining the dominant effect
of flavopiridol in mediating G2 arrest. These results sug-
gest that the effect of flavopiridol in inducing p53 is
upstream of the mechanism by which 4OH-Tam inhibits
p53.
Interestingly, we found that p53 differentially regu-
lated flavopiridol-mediated cell cycle arrest and apopto-
sis. RNA interference analysis of p53 indicated that
while flavopiridol-mediated G2 arrest was dependent on
p53, flavopiridol-mediated apoptosis (but not that
mediated by 4OH-Tam) was countered by p53. This is
an intriguing observation since there was a clear
enhancement of apoptosis induced by flavopiridol when
p53 was abrogated by RNA interference (Figure 6D).
Previously it has been reported that lack of p53
enhances radio-sensitivity via activation of E2F-1 and
induction of caspase 8 activity in glioma cells [40].
Furthermore, radio-sensitivity of keratinocytes was
enhanced by abrogation of p53 and was mediated by
down-regulation of anti-apoptotic proteins Mcl-1 and
Bcl-XL [41]. To our knowledge, this is the first report
which indicates that down-modulation of p53 also
enhances drug-induced apoptosis. Our results indicate
that the potency of flavopiridol can be enhanced if p53
can be inhibited by some means.
Most RTs express p53, though a percentage of RTs do
show mutations within the p53 gene [44-46]. Some RT
cell lines express p53 at high levels or with increased
nuclear distribution, however, the p53 pathway has been
tested and considered to be functionally intact [42,44].
The mutation status of p53 in MON RT cells has not
been determined but the proper expression of p53 and
responsiveness of p21
Waf1 to p53 levels leads us to
believe that the p53 pathway is intact in these cells.
However, other studies indicated that the pro-apoptotic
pathway downstream of p53 may be dysfunctional in
MON cells but the exact nature of this defect is
unknown [43]. Although this defect in the pro-apoptotic
pathway downstream of p53 could account for the
observed effects reported here, our observation indicates
that flavopiridol-induced apo p t o s i si si n h i b i t e db yp 5 3 .
More experiments are needed to delineate the exact role
of the p53 pathway in flavopiridol-induced cytotoxicity
in MON and other RT cells.
The relationship of flavopiridol and p53 in inducing
apoptosis seems to be paradoxical in different cell lines
and in different treatment approaches. Perhaps this is
related to the paradoxical anti-apoptotic activities of p53
itself in various cancer cells [47]. The activities of p53
are cell type dependent and can be either pro-apoptotic
and/or pro-survival. For example, in RT cells p53 is
deleterious to flavopiridol-mediated apoptosis, but in
other cancer cell lines flavopiridol-induced apoptosis is
actually dependent on p53. An example is provided by
Ambrosini et al who demonstrated that enhanced apop-
tosis induced by a combination therapy of flavopiridol
with a G1-arrest-inducing agent (namely SN-38) was
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flavopiridol and SN-38 was tested on isogenic pairs of
cells differing only in p53. They found that the
enhanced apoptosis by combination of flavopiridol and
SN-38 was observed only in p53
+/+ c e l l s .S i m i l a rt oS N -
38, 4OH-Tam also induces G1 arrest in our system,
however; the effects of combining flavopiridol with
4OH-Tam obtained in RT cells are different in terms of
inducing apoptosis. While flavopiridol-mediated G2
arrest was dependent on p53, flavopiridol-induced apop-
tosis was abrogated by p53 (Figure 6C and 6D). On the
contrary, p53 had no effect on 4OH-Tam-mediated
apoptosis. Because of these results, we believe that p53
has compromising effects on flavopiridol-induced apop-
tosis in RT cells, similar to the effect of p53 in protect-
ing cells from radiation induced apoptosis as discussed
above.
Our studies involving p53 knock-down indicate that
stimulation of p53 by flavopiridol limits its ability to
induce apoptosis in RT cells. Thus, it is possible that
4OH-Tam increases the effects of flavopiridol because it
down-modulates p53 in addition to inducing apoptosis
by p53-independent mechanisms. This new understand-
ing of p53’s role in drug-induced apoptosis in RT cells
might shed light on the mechanism of resistance to
therapies exhibited by these tumors. Also, evaluation of
p53 levels induced by flavopiridol and other treatments
may be necessary to implement effective treatment stra-
tegies for RTs.
Flavopiridol induces apoptosis by additional p53-inde-
pendent mechanisms. It is able to block RNA polymer-
ase II phosphorylation by inhibiting cdk 9, thereby
blocking transcriptional elongation. This activity, as well
as flavopiridol’s ability to reduce antiapoptotic protein
MCL-1, has been implicated in the induction of apopto-
sis in multiple myeloma cell lines [49]. Additionally,
induction of the mitochondrial permeability transition
by flavopiridol has been correlated with induction of
apoptosis in chronic lymphocytic leukemia cells [50].
These functions of flavopiridol may also contribute to
the apoptosis occurring in RT cells in a p53-indepen-
dent manner.
RTs are notoriously resistant to therapeutic interven-
tions [3]. Potent chemotherapy in combination with sur-
gery and radiotherapy have proven futile in increasing
survival rates and only a handful of RT survivors have
been reported [2]. Therefore, efforts to develop molecu-
larly targeted therapies are needed. Based on the mole-
cular understanding of RTs, it is known that INI1/
hSNF5 mediates tumor suppression in part by targeting
cyclins and cdks [7-9]. Furthermore, cyclin D1 is up-
regulated in, and necessary for, rhabdoid tumorigenesis
[9,12]. Thus, it appears that therapeutically inhibiting
the cyclin/cdk pathway is a novel, targeted treatment
strategy for RTs. Our report suggests that combination
of flavopiridol and 4OH-Tam could be used as a novel
combination therapy for RTs. Furthermore, this combi-
nation could be effective in inducing apoptosis in other
tumor models, especially those lacking p53.
At this point, the concentrations of 4OH-Tam
required to increase the effects of flavopiridol appear to
be high. Nevertheless, in the pediatric population, where
RTs most often occur, it has been reported that high
doses of tamoxifen (100 mg/m
2 twice a day) can be
administered with minimal toxicity [51]. Furthermore, in
cases where sustained high concentrations (≥ 10 uM) of
4OH-Tam may not be attained, alternative formulations,
such as a liposomal formulation, of both tamoxifen and
4OH-Tam have been used that would result in the
delivery of high concentrations directly to the tumor
[52]. Therefore, further preclinical and clinical studies to
test the efficacy of these drugs in children may lead to
the development of definitive therapeutic strategies
against RTs that may improve prognosis.
Additional material
Additional File 1: Flavopiridol- and 4OH-Tam-induced caspase
profiles in MON cells: A-I. Panels represent kinetics of induction of
caspase activities in MON cells transfected with control (+Cy3) or p53
(+p53) siRNAs and then treated with 100 nM Flavopiridol (F100), 5 μM
4OH-Tam (T5), or both (F100T5) for two days. J-K. Graphic representation
of caspase 2 and 3 activities induced by the drugs (as in A-I) in the
presence of control (Cy3) or p53 siRNA (p53), at 24 hr. time point, in the
presence or absence of specific caspase 2 and 3 inhibitors, respectively.
The values illustrate the average of two independent experiments.
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